Evaluation of the Potential Benefits of Itopride in the Management of Patients With Metabolic Associated Fatty Liver Disease

REC-H-PhBSU-23006

Objective of this study is to determine the clinical benefits of itopride in improvement of MAFLD

2023-12-28

2024-12-01

2025-12-01

Not yet recruiting

Early phase I

60

Inclusion Criteria: * Patients presented to hepatology clinic . -Patients are diagnosed by ultrasonography and laboratory tests for liver and lipids. - - * Patients with comorbidites like hypertension,diabetes,dyslipidemia Exclusion Criteria: * Exclusion criteria included the presence of liver disease due to any of the following: viral hepatitis (HBV, HCV) * acute systemic disease * cystic fibrosis, coeliac disease * suspicion of muscular dystrophy, alpha-1-antitrypsin deficiency * metabolic inherited diseases * autoimmune hepatitis, drug toxicity and drugs known to induce steatosis (e.g. valproate, amiodarone orprednisone). * Patients were also excluded if body weight and carbohydrate metabolism were altered by the use of parenteral nutrition * protein malnutrition * previous gastrointestinal surgery * structural abnormalitiesof the gastrointestinal tract or neurological impairment. * the use of nonsteroidal anti-inflammatory drugs,antibiotics,sglt2,dpp4,statins,glp1 * probiotics or anti-secretory drugs capable of causing achlorhydria within 2 months preceding enrolmentwere also considered exclusion criteria. * Patient with age below 18 or above 60

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 60, 'type': 'ESTIMATED'}}

2023-10-31